Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis
- PMID: 22470121
- PMCID: PMC3370767
- DOI: 10.1128/AAC.06460-11
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis
Abstract
Bacterial factors may contribute to the global emergence and spread of drug-resistant tuberculosis (TB). Only a few studies have reported on the interactions between different bacterial factors. We studied drug-resistant Mycobacterium tuberculosis isolates from a nationwide study conducted from 2000 to 2008 in Switzerland. We determined quantitative drug resistance levels of first-line drugs by using Bactec MGIT-960 and drug resistance genotypes by sequencing the hot-spot regions of the relevant genes. We determined recent transmission by molecular methods and collected clinical data. Overall, we analyzed 158 isolates that were resistant to isoniazid, rifampin, or ethambutol, 48 (30.4%) of which were multidrug resistant. Among 154 isoniazid-resistant strains, katG mutations were associated with high-level and inhA promoter mutations with low-level drug resistance. Only katG(S315T) (65.6% of all isoniazid-resistant strains) and inhA promoter -15C/T (22.7%) were found in molecular clusters. M. tuberculosis lineage 2 (includes Beijing genotype) was associated with any drug resistance (adjusted odds ratio [OR], 3.0; 95% confidence interval [CI], 1.7 to 5.6; P < 0.0001). Lineage 1 was associated with inhA promoter -15C/T mutations (OR, 6.4; 95% CI, 2.0 to 20.7; P = 0.002). We found that the genetic strain background influences the level of isoniazid resistance conveyed by particular mutations (interaction tests of drug resistance mutations across all lineages; P < 0.0001). In conclusion, M. tuberculosis drug resistance mutations were associated with various levels of drug resistance and transmission, and M. tuberculosis lineages were associated with particular drug resistance-conferring mutations and phenotypic drug resistance. Our study also supports a role for epistatic interactions between different drug resistance mutations and strain genetic backgrounds in M. tuberculosis drug resistance.
Figures


Similar articles
-
Multi-drug resistance and compensatory mutations in Mycobacterium tuberculosis in Vietnam.Trop Med Int Health. 2025 May;30(5):426-436. doi: 10.1111/tmi.14104. Epub 2025 Mar 13. Trop Med Int Health. 2025. PMID: 40078052 Free PMC article.
-
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.BMC Infect Dis. 2019 Jan 3;19(1):3. doi: 10.1186/s12879-018-3638-z. BMC Infect Dis. 2019. PMID: 30606116 Free PMC article.
-
Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates.J Antimicrob Chemother. 2014 Sep;69(9):2369-75. doi: 10.1093/jac/dku161. Epub 2014 May 22. J Antimicrob Chemother. 2014. PMID: 24855126
-
Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients.Tuberculosis (Edinb). 2022 Jul;135:102209. doi: 10.1016/j.tube.2022.102209. Epub 2022 Apr 30. Tuberculosis (Edinb). 2022. PMID: 35550524 Review.
-
Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis.Tuberculosis (Edinb). 2021 Jul;129:102091. doi: 10.1016/j.tube.2021.102091. Epub 2021 May 21. Tuberculosis (Edinb). 2021. PMID: 34090078 Review.
Cited by
-
Identification of potent inhibitors of ATP synthase subunit c (AtpE) from Mycobacterium tuberculosis using in silico approach.Heliyon. 2021 Nov 29;7(12):e08482. doi: 10.1016/j.heliyon.2021.e08482. eCollection 2021 Dec. Heliyon. 2021. PMID: 34934830 Free PMC article.
-
Clinical and bacteriological characteristics associated with clustering of multidrug-resistant tuberculosis.Int J Tuberc Lung Dis. 2017 Jul 1;21(7):766-773. doi: 10.5588/ijtld.16.0510. Epub 2017 May 16. Int J Tuberc Lung Dis. 2017. PMID: 28513421 Free PMC article.
-
Insights into the processes that drive the evolution of drug resistance in Mycobacterium tuberculosis.Evol Appl. 2018 Jun 21;11(9):1498-1511. doi: 10.1111/eva.12654. eCollection 2018 Oct. Evol Appl. 2018. PMID: 30344622 Free PMC article. Review.
-
Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02175-18. doi: 10.1128/AAC.02175-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30718257 Free PMC article.
-
Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.Clin Microbiol Rev. 2023 Dec 20;36(4):e0008823. doi: 10.1128/cmr.00088-23. Epub 2023 Nov 30. Clin Microbiol Rev. 2023. PMID: 38032192 Free PMC article. Review.
References
-
- Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603–662 - PubMed
-
- Borrell S, Gagneux S. 2009. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1456–1466 - PubMed
-
- Böttger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin. Microbiol. Infect. 17:1128–1134 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources